Business Wire

QUECTEL-WIRELESS

Share
Quectel IoT Modules Significantly More Secure Than Industry Average According to Finite State

Quectel Wireless Solutions, a global IoT solutions provider, today announces that, according to a recent milestone report by Finite State, an independent third-party cybersecurity firm, nearly 95% of all Quectel modules shipped to the United States since the beginning of 2022 have industry-leading security scores based on penetration testing and binary analysis by Finite State.

The report highlights a notable enhancement in Quectel's security position, expanding the number of modules tested and with scores across the tested modules improving from an average of 33 to 18, up from an average of 62 to 24 in previous testing. This represents a substantial improvement, as both the initial and revised scores significantly surpass the industry average of 98 with the lowest (best) score of 10. Further, the number of and severity of vulnerabilities Finite State did identify in Quectel products or modules are significantly less than the industry standard and revealed a very limited attack surface. Those issues Finite State did discover have been quickly remedied by Quectel.

This advanced phase of testing leverages Finite State's security technologies and expertise to conduct an exhaustive third-party evaluation of Quectel's modules. The advanced testing encompasses an array of sophisticated security assessments designed to fortify Quectel's modules against the evolving landscape of cyber threats, including binary analysis of numerous Quectel products and both penetration testing and binary analysis of several Quectel cellular modules.

"Entering this next phase of security testing with Finite State underscores our relentless pursuit of the highest security standards for our products," stated Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "Our continued collaboration is a reflection of our commitment to exceed industry security expectations, ensuring our customers benefit from the most secure and reliable communication modules available – tested and verified by one of the most trusted US cyber security firms. We’re thrilled that the latest report from Finite State demonstrates our commitment and progress."

The continued integration of Finite State into Quectel’s transparency and security program reaffirms Quectel’s commitment to pioneering unparalleled security practices in the IoT and telecommunications sectors. Quectel has made a measurable improvement in key areas such as the security health of the code, the sophistication of the vulnerability management process, and the transparency of its software supply chain.

The program is strategically designed with three key goals to address the pressing issues in cybersecurity today:

  1. Implementing the Finite State Platform into Quectel's DevSecOps procedures, which enhances firmware binary analysis, manages vulnerabilities efficiently, and offers specific recommendations for remediation.
  2. Developing and sharing Software Bill of Materials (SBOM) and Vulnerability Exploitability Exchange (VEX) documents for each of Quectel's products, which promotes a transparent environment and provides critical insights into the software components of Quectel's devices along with any vulnerabilities they may contain.
  3. Conducting comprehensive manual penetration tests by Finite State's expert Red Team, which augments automated testing methods and delivers detailed security evaluations for Quectel's product line.

Matt Wyckhouse, CEO of Finite State, commented, "Progressing to this next phase of security testing demonstrates Quectel’s commitment to leading the industry with transparent, rigorous cybersecurity practices. Quectel's willingness to subject their products to such rigorous scrutiny is commendable and sets a new industry standard to further safeguard the IoT ecosystem."

The outcome of this continued engagement is anticipated to enhance the security framework of Quectel's modules and inspire a shift towards more rigorous security standards across the telecommunications industry. Quectel is dedicated to sharing insights and best practices gleaned from this process, contributing to a safer, more secure digital future.

In addition to the activity with Finite State, Quectel is actively pursuing collaboration with multiple standards-setting organizations to enhance and commit to a more rigorous set of security requirements. This initiative aims to achieve key security certifications from both industry and governmental bodies, underlining Quectel's dedication to advancing security standards within the sector.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240318703729/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 08:00:00 CET | Press release

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ®BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI® (eculizumab), OBODENCE® (denosumab), and XBRYK® (denosumab)Pre-filled syringe (PFS) presentation to become available in Europe in the second quarter of 2026 Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizuma

Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 15:00:00 CET | Press release

The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch

Aster Guardians Global Nursing Award 2026 Worth $250,000 Extends Deadline Till 11th January 202631.12.2025 14:08:00 CET | Press release

Due to an extraordinary global response of over 134,000 registrations from 214 countries, the submission deadline has been extended.Nurses worldwide can submit their nominations via www.asterguardians.com The Aster Guardians Global Nursing Award 2026, an initiative from Aster DM Healthcare – a leading integrated healthcare provider, has announced the extension of its deadline to January 11, 2026. The awards have already received over 134,000 registrations from 214 countries, highlighting its growing global reach and recognition among nurses worldwide. Nurses from around the world can submit their nominations through the dedicated platform at www.asterguardians.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231986766/en/ Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire) This year, the prestigious award will be hosted in New Delhi, India, celebrating nursing excellence on a truly global stage. T

Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation31.12.2025 11:59:00 CET | Press release

Tecnotree, a global digital platform and services provider for communications service providers (CSPs), today announced that it has been referenced as a Representative Provider alongside Google, Anthropic, Dropzone AI, DRUID, Palo Alto Networks, and Pegasystems in the Gartner® Innovation Insight: “AI SOC Agents Accelerate CSP SecOps Transformation,” published in December 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231210303/en/ Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation The Gartner Innovation Insight examines the emerging role of AI-driven Security Operations Centre (SOC) agents in CSP environments, outlining how these agents are used to automate and augment security operations across signalling, core networks, RAN, Open RAN, and roaming domains. The research discusses use cases such as alert triage, investigation support, thr

UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy30.12.2025 15:15:00 CET | Press release

The newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by SMA Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230695275/en/ World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospital in Dubai, UAE, along with parents, and the hospital team. (Photo: AETOSWire) SMA is a rare neuromuscular disorder that progressively weakens muscles responsible for movement and breathing. This newly licensed one-time therapy addresses the root genetic cause

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye